What was the primary driver of Pfizer's revenue growth in the reported period?

The primary driver of Pfizer's revenue growth was the strong performance of its Pharmaceuticals segment, particularly driven by sales volume of in-line products and revenue generated from product alliances. Key drugs like Lipitor and Norvasc continued to show significant sales increases.

How did merger-related costs impact the company's results?

Merger-related costs, primarily from the integration of Warner-Lambert, decreased significantly by 79% year-over-year for the nine months ended September 30, 2001. While still a notable expense at $589 million, the reduction indicates progress in integrating the acquired business and suggests a lessening impact on profitability going forward.

What is the company's outlook for earnings per share (EPS) for the full year 2001 and 2002?

Pfizer is comfortable with its projected full-year 2001 diluted EPS from continuing operations of $1.30 (excluding certain significant items and merger-related costs). The company reaffirms its projection of diluted EPS from continuing operations in 2002 at $1.56 or better, on the same basis.

What is the company's financial position regarding cash and debt?

Pfizer reported a strong net financial asset position of $5.5 billion as of September 30, 2001, an increase from $4.1 billion at the end of 2000. This reflects robust operating cash flows and strategic debt issuance, partially offset by investments and share repurchases. Cash and cash equivalents along with short-term investments totaled $9.7 billion, indicating ample liquidity.

PFE 10-Q Filed Nov 13, 2001

Summary

Pfizer Inc. reported strong financial performance for the nine months ended September 30, 2001, with a significant increase in income from continuing operations, up 151% to $5.8 billion compared to the prior year period. This growth was driven by a 9% increase in total revenues to $23.2 billion, primarily fueled by robust sales in the Pharmaceuticals segment, particularly from key products like Lipitor and Norvasc. The company also successfully managed its expenses, with cost of sales and selling, informational, and administrative expenses decreasing as a percentage of revenue, indicating improved operational efficiency. Despite the positive operational results, the company incurred substantial merger-related costs, largely from the integration of Warner-Lambert, although these costs significantly decreased compared to the previous year. Pfizer also continues to actively manage its capital structure, evidenced by strong operating cash flow and strategic share repurchases. Investors should note the ongoing legal proceedings, which are typical for a company of Pfizer's size and scope in the pharmaceutical industry, though management believes they will not materially impact the company's financial position.

Key Highlights

1Net income from continuing operations surged 151% year-over-year for the nine months ended September 30, 2001, reaching $5.8 billion, with diluted EPS at $0.92.
2Total revenues increased by 9% to $23.2 billion for the nine months ended September 30, 2001, driven by strong Pharmaceutical segment performance.
3Pharmaceuticals segment revenue grew 12% to $19.3 billion for the nine months ended September 30, 2001, with major contributions from Cardiovascular and Central Nervous System products.
4Merger-related costs significantly decreased by 79% to $589 million for the nine months ended September 30, 2001, reflecting progress in integrating acquired businesses.
5Net cash provided by operating activities more than doubled to $6.8 billion for the nine months ended September 30, 2001, indicating strong cash generation.
6The company repurchased approximately 34 million shares of common stock in Q3 2001 for $1.34 billion under a new $5 billion share repurchase program.

PFIZER INC Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions